211 related articles for article (PubMed ID: 30101054)
1. Histone H3 Mutations in Cancer.
Wan YCE; Liu J; Chan KM
Curr Pharmacol Rep; 2018; 4(4):292-300. PubMed ID: 30101054
[TBL] [Abstract][Full Text] [Related]
2. Histone H3K27M Mutation in Brain Tumors.
El-Hashash AHK
Adv Exp Med Biol; 2021; 1283():43-52. PubMed ID: 33155136
[TBL] [Abstract][Full Text] [Related]
3. Histone Lysine-to-Methionine Mutation as Anticancer Drug Target.
Yang J; Qiu Q; Chen L
Adv Exp Med Biol; 2021; 1283():85-96. PubMed ID: 33155140
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
5. Oncohistones: Hijacking the histone code.
Sahu V; Lu C
Annu Rev Cancer Biol; 2022 Apr; 6():293-312. PubMed ID: 36589281
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of cancer: Oncohistones in action.
Qiu L; Hu X; Jing Q; Zeng X; Chan KM; Han J
J Genet Genomics; 2018 May; 45(5):227-236. PubMed ID: 29804713
[TBL] [Abstract][Full Text] [Related]
7. Emerging Advances in Combinatorial Treatments of Epigenetically Altered Pediatric High-Grade H3K27M Gliomas.
Leszczynska KB; Jayaprakash C; Kaminska B; Mieczkowski J
Front Genet; 2021; 12():742561. PubMed ID: 34646308
[TBL] [Abstract][Full Text] [Related]
8. Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma.
Zhang X; Zhang Z
Trends Cancer; 2019 Dec; 5(12):799-808. PubMed ID: 31813457
[TBL] [Abstract][Full Text] [Related]
9. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State.
Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M
Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023
[TBL] [Abstract][Full Text] [Related]
10. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
11. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG.
Nikolaev A; Fiveash JB; Yang ES
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975
[TBL] [Abstract][Full Text] [Related]
12. Histone tail analysis reveals H3K36me2 and H4K16ac as epigenetic signatures of diffuse intrinsic pontine glioma.
An S; Camarillo JM; Huang TY; Li D; Morris JA; Zoltek MA; Qi J; Behbahani M; Kambhampati M; Kelleher NL; Nazarian J; Thomas PM; Saratsis AM
J Exp Clin Cancer Res; 2020 Nov; 39(1):261. PubMed ID: 33239043
[TBL] [Abstract][Full Text] [Related]
13. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas.
Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ
Front Oncol; 2019; 9():92. PubMed ID: 30873381
[TBL] [Abstract][Full Text] [Related]
14. Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers.
Klein BJ; Krajewski K; Restrepo S; Lewis PW; Strahl BD; Kutateladze TG
Epigenetics; 2018; 13(7):683-692. PubMed ID: 30045670
[TBL] [Abstract][Full Text] [Related]
15. Histone H2B Mutations in Cancer.
Wan YCE; Chan KM
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34205231
[TBL] [Abstract][Full Text] [Related]
16. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
[TBL] [Abstract][Full Text] [Related]
17. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
[TBL] [Abstract][Full Text] [Related]
18. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas.
Chung C; Sweha SR; Pratt D; Tamrazi B; Panwalkar P; Banda A; Bayliss J; Hawes D; Yang F; Lee HJ; Shan M; Cieslik M; Qin T; Werner CK; Wahl DR; Lyssiotis CA; Bian Z; Shotwell JB; Yadav VN; Koschmann C; Chinnaiyan AM; Blüml S; Judkins AR; Venneti S
Cancer Cell; 2020 Sep; 38(3):334-349.e9. PubMed ID: 32795401
[TBL] [Abstract][Full Text] [Related]
19. The H3K27M mutation alters stem cell growth, epigenetic regulation, and differentiation potential.
Kfoury-Beaumont N; Prakasam R; Pondugula S; Lagas JS; Matkovich S; Gontarz P; Yang L; Yano H; Kim AH; Rubin JB; Kroll KL
BMC Biol; 2022 May; 20(1):124. PubMed ID: 35637482
[TBL] [Abstract][Full Text] [Related]
20. The dark side of histones: genomic organization and role of oncohistones in cancer.
Amatori S; Tavolaro S; Gambardella S; Fanelli M
Clin Epigenetics; 2021 Apr; 13(1):71. PubMed ID: 33827674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
